Shire PLC (SHP) To Go Ex-Dividend on September 7th
Shire PLC (LON:SHP) announced a dividend on Thursday, August 3rd, Upcoming.Co.Uk reports. Investors of record on Thursday, September 7th will be paid a dividend of GBX 3.85 ($0.05) per share by the biopharmaceutical company on Friday, October 20th. This represents a yield of 0.1%. The ex-dividend date of this dividend is Thursday, September 7th. The official announcement can be seen at this link.
Shares of Shire PLC (LON SHP) opened at 3963.00 on Wednesday. The company has a 50-day moving average of GBX 3,974.43 and a 200-day moving average of GBX 4,439.19. Shire PLC has a 12 month low of GBX 3,603.50 and a 12 month high of GBX 5,377.00. The stock’s market capitalization is GBX 35.92 billion.
TRADEMARK VIOLATION WARNING: “Shire PLC (SHP) To Go Ex-Dividend on September 7th” was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.dailypolitical.com/2017/09/06/shire-plc-shp-to-go-ex-dividend-on-september-7th.html.
A number of research analysts have recently issued reports on SHP shares. Barclays PLC restated an “overweight” rating and issued a GBX 6,300 ($81.36) price target on shares of Shire PLC in a research report on Monday, July 3rd. Beaufort Securities restated a “long term buy” rating and issued a GBX 4,900 ($63.28) price target (down from GBX 6,200 ($80.07)) on shares of Shire PLC in a research report on Friday, August 4th. J P Morgan Chase & Co restated an “overweight” rating and issued a GBX 6,000 ($77.49) price target on shares of Shire PLC in a research report on Friday, May 19th. Deutsche Bank AG restated a “buy” rating and issued a GBX 6,100 ($78.78) price target on shares of Shire PLC in a research report on Friday, May 19th. Finally, Citigroup Inc. restated a “buy” rating and issued a GBX 6,300 ($81.36) price target on shares of Shire PLC in a research report on Tuesday, August 22nd. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of GBX 5,878.47 ($75.92).
In related news, insider Flemming Ornskov bought 8,400 shares of the stock in a transaction on Tuesday, August 22nd. The shares were purchased at an average price of GBX 3,665 ($47.33) per share, with a total value of £307,860 ($397,597.83). Also, insider Dominic Blakemore bought 152 shares of the stock in a transaction on Friday, June 30th. The shares were bought at an average cost of GBX 4,255 ($54.95) per share, for a total transaction of £6,467.60 ($8,352.83).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.